+7 495 640 5275
Keeping clients informed is one of our major priorities. Be the first to get updates on regulatory issues and news.
1 December 2015
During the years of Pharma 2020 programme’s existence about 150 billion roubles was invested, around half of which was invested by Russian companies; the other half was invested by companies from abroad.
The number of Russian medicinal product manufacturers amounted to 25.2% in 2014; in the first six months of 2015, the number grew up to 28.8% and amounted to 29.5 in public procurement. The number of Russian products in the “7 nosologies” programme grew since 2011 from 4.2% to 44% in the first six months of the year 2015. President Putin instructed that the number of Russian-made medical products should amount to 90% of all life-saving and essential drugs on the list by 2018. This wish is being put into action in due time. Based on the results of the first six months of the year 2015, the number hit 69%, with the target being 67%. The increase in the amount of Russian manufacturing is due to the localization of international companies’ manufacturing. According to the Ministry of Industry and Trade’s representative, the last 10 years saw 72 foreign-owned companies localize their manufacture in Russia. They produce INNs, 195 of which are life-saving and essential drugs.